Gallant Reports | FDA Completes Safety for Their First Ready-to-Use Stem Cell Therapy for Refractory FCGS

With this core milestone achieved, Gallant advances toward delivering the potential first FDA-approved, off-the-shelf stem cell therapy—and introducing a new category in veterinary medicine